Pneumocystis jirovecii: A peculiar fungus posing particular problems for therapy and prophylaxis

Mycoses

Volumn 55, Issue SUPPL.1, 2012, Pages 1-7

  Hof, H ^a  

^a Labor Limbach   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ATOVAQUONE; CASPOFUNGIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; ERGOSTEROL; MICAFUNGIN; PENTAMIDINE; PREDNISONE; PRIMAQUINE;

ANTIBIOTIC THERAPY; ARTICLE; COUGHING; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; ERYTHEMA; FEVER; FUNGAL COLONIZATION; HEART ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER INJURY; MICROSCOPY; NEPHROTOXICITY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RASH; REAL TIME POLYMERASE CHAIN REACTION; SPUTUM ANALYSIS; TACHYPNEA;

FUNGI; MAMMALIA; PNEUMOCYSTIS; PNEUMOCYSTIS JIROVECII;

EID: 84859381419     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02159.x     Document Type: Article

References (42)

1. Goldman AS, Goldman LR, Goldman TA. What caused the epidemic of Pneumocystis pneumonia in European premature infants in the mid-20th century? Pediatrics 2005; 115: 725-36.
2. Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Eukaryot Microbiol 1999; 46: 89S-92S.
3. Thomas CF, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007; 5: 298-308.
4. Krajicek BJ, Thomas CF, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med 2009; 30: 265-278.
5. De Castro N, Neuville S, Sarfati C et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005; 36: 879-883.
6. Marie I, Guglielmino E. Infections opportunistes non tuberculeuses au cours du traitement par les antiTNFα. Rev Med Intern 2010; 21: 353-360.
7. Readhead SA, Cushion MT, Frenkel JK, Stringer JR. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaroyt Microbiol 2006; 53: 2-11.
8. Wakefield AE. Pneumocystis carinii. Brit Med Bull 2002; 61: 175-188.
9. Hof H. A new, broad spectrum azole antigfungal: posaconazole - mechanisms of action and resistance, spectrum of activity. Mycoses 2006; 1: 2-6.
10. Matsumoto Y., Matsuda S., Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool 1991; 38: 6S-7S.
11. Villegas LR, Kottom TJ, Limper AH. Characterization of PCEng2 a {beta}-1, 3-endoglucanase homologue in Pneumocystis carinii with activity in cell wall regulation. Am J Respir Cell Mol Biol 2010; 43: 192-200.
12. Aliouat-Denis C-M, Martinez A, Aliouat EM, Pottier M, Gantois N, Dei-Cas E. The pneumocystis life cycle. Mem Inst Oswaldo Cruz 2009; 104: 419-426.
13. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007; 44: 1143-1149.
14. Nevez G, Chabé M, Rabodonirina M et al. Nosocomial Pneumocystis jirovecii infections. Parasite. 2008; 15: 359-65.
15. Mofenson LM, Brady MT, Danner SP et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009; 58:1-166.
16. Kordek A, Kolodziejczyk L, Adamska M et al. Prematurity and protracted mechanical ventilation as risk factors for Pneumocystis jiroveci infection in HIV-negative neonates in an intensive care unit. Turk J Pediatr 2007; 49: 158-164.
17. Hof H, Schnülle P. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses 2008; 51(Suppl 1): 65-67.
18. Miller RF, Huang L. Pneumocystis jirovecii. In: Warrell DA, Cox TM, Firth JD (eds), Oxford Textbook of Medicine, 5th edn. Oxford: Oxford University Press 2010; 1028-1032.
19. Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997; 10: 401-418.
20. Anuradha SA. Extrapulmonary Pneumocystis carinii infection in AIDS patient: a case report. Acta Cytol 2007; 51: 599-601.
21. Swain SD, Han S, Harmsen A, Shampeny K, Harmsen AG. Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. Am J Pathol 2007; 171: 790-799.
22. Wilson JW, Limper AH, Grys TE, Karre T, Wengenack NL, Binnicker MJ. Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. Diagn Microbiol Infect Dis 2011; 69: 145-152.
23. Friaza V, Morilla R, Respaldiza N, de la Horra C, Calderón EJ. Pneumocystis jiroveci dihydropteroate synthase gene mutations among colonized individuals and Pneumocystis pneumonia patients from Spain. Postgrad Med 2010; 122: 24-28.
24. Del Bono V, Mularoni A, Furfaro E et al. Clinical evaluation of a (1, 3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol. 2009; 16: 1524-1526.
25. Safrin S, Finkelstein DM, Freiberg J et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 125: 792-802.
26. El-Sadr WM, Murphy RL, Yurik TM et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998; 339: 1889-1895.
27. Meyers B, Borrego F, Papanicolau G. Pneumocystis pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study. Liver Transpl 2001; 7: 750-751.
28. Groll AH, Ritter J, Müller FM. Guidelines for prevention of Pneumocystis carinii pneumonitis in children and adolescents with cancer. Klin Paediatr 2001; 213(Suppl 1): A38-49.
29. Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneuomocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004; 38: 76-78.
30. Maschmeyer G., Beinert T., Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients. Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology (DGHO). European J Cancer 2009; 45: 2462-2472.
31. Limper AH, Knox KS, Sarosi GA et al. An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183: 96-128.
32. Morris A., Creasman J., Turner J., Luce J.M., Wachter R.M., Huang L. Intensive care of human deficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166: 262-267.
33. Patel N, Koziel H. Pneumocystis jiroveci pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat Respir Med 2004; 3: 381-397.
34. Furuta T, Muramatsu H, Fujie A, Abudullah NR, Kojima S. Therapeutic effects of water-soluble echinocandin compounds on Pneumocystis pneumonia in mice. Antimicrob Ag Chemother 1998; 42: 37-39.
35. Powles MA, Liberator P, Anderson J et al. Efficacy of MK-991 (L-743, 872)), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Ag Chemother 1998; 4: 1985-1989.
36. Cushion MT, Linke MJ, Ashbaugh A et al. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 2010; 5: e8524.
37. Annaloro C, Della Volpe A, Usardi P, Lambertenghi Deliliers G. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 2006; 25: 52-54.
38. Mu XD, Que CL, He B, Wang GF, Li HC. Caspofungin in salvage treatment of severe Pneumocystis pneumonia: case report and literature review. Chin Med J 2009; 122: 996-999.
39. Beltz K, Kramm CM, Laws HJ, Schroten H, Wessalowski R, Göbel U. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin Paediat. 2006; 218: 177-179.
40. Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 2006; 43: 92-94.
41. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007; 18: CD005590.
42. Grewal P, Brassard A. Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review. J Cutan Med Surg. 2009; 13: 308-312.